NEW YORK – Historically focused on clinical sequencing, Fulgent Genetics recently saw dramatic increases in its COVID-19 RT-qPCR testing business. While the firm plans to continue to grow its PCR business in 2021, it also expects to attract attention to its next-generation sequencing tests — including for SARS-CoV-2 variants — as well as to offer new products.
Fulgent is also positioning its at-home self-collection brand, Picture Genetics, to be at the forefront of a potential new market for consumer-initiated clinical sequencing.